Bury, Didi http://orcid.org/0000-0003-2943-1085
Tissing, Wim J. E. http://orcid.org/0000-0001-9101-507X
Muilwijk, Eline W. http://orcid.org/0000-0003-2348-1233
Wolfs, Tom F. W. http://orcid.org/0000-0003-2986-8404
Brüggemann, Roger J. http://orcid.org/0000-0002-7618-725X
Article History
Accepted: 28 January 2021
First Online: 18 May 2021
Declarations
:
: No sources of funding were received for the preparation of this article.
: Didi Bury, Wim J.E. Tissing, Eline W. Muilwijk, Tom F.W. Wolfs, and Roger J. Brüggemann have no conflicts of interest that are directly relevant to the content of this article. Disclosures outside of this work: Roger J. Brüggemann has served as a consultant to Astellas Pharma, Inc., F2G, Amplyx, Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc., and has received unrestricted and research grants from Astellas Pharma, Inc., Gilead Sciences, Merck Sharp & Dohme Corp., Mundipharma, and Pfizer, Inc. All contracts were through Radboudumc, and all payments were invoiced by Radboudumc.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: DB performed the literature search, selected articles, and drafted the manuscript together with RB. WT, TW, and EM provided a critical revision of the manuscript. All authors approved of the final version.